Molecular mechanism of vacuolar formation associated with cell death induced by CDK4/6 inhibitor abemaciclib

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Tanaka, Yoshinori [2 ]
Okimoto, Tomoya [1 ]
Ikeda, Toshikatsu [1 ]
Hara, Tomoyo [1 ]
Takeya, Kosuke [2 ]
Takano, Naoharu [3 ]
Hiramoto, Masaka [3 ]
Aizawa, Shin [1 ]
Miyazawa, Keisuke [3 ]
Eto, Masumi [2 ]
Hirai, Shuichi [1 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morphol, Sch Med, Tokyo, Japan
[2] Okayama Univ Sci, Dept Vet Med, Biochem Unit, Okayama, Japan
[3] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3317
引用
收藏
页码：1741 / 1741
页数：1
相关论文
共 50 条
  • [31] Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
    Sun, Chao-Yue
    Talukder, Milton
    Cao, Di
    Chen, Cun-Wu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] Successful continuance of CDK4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report
    Ozawa, Yuki
    Fujimiya, Tatsuhiro
    Shimada, Akihiko
    Okazawa, Akira
    Kusano, Junichi
    Yamamoto, Ryusei
    Hyasashi, Seiichi
    ANTI-CANCER DRUGS, 2024, 35 (01) : 89 - 92
  • [33] Characterization of a novel potent and selective CDK4/6 inhibitor and a resistance mechanism
    Dai, Kang
    Li, Cong
    Liang, Lingming
    Rong, Minging
    Orf, Jessica
    Keegan, Kathy
    Li, Zhihong
    Fu, Jiasheng
    Ma, Ji
    Carlson, Tim
    McGee, Larry
    Medina, Julio
    Kamb, Alexander
    Wickramasinghe, Dineli
    CANCER RESEARCH, 2012, 72
  • [34] Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib
    Tiedt, Ralph
    Delach, Scott
    Kovats, Steven
    Horn, Thomas
    Acker, Michael
    Engstler, Barbara Schacher
    Caponigro, Giordano
    Su, Fei
    CANCER RESEARCH, 2017, 77
  • [35] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [36] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
    Barroso-Sousa, Romualdo
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    BREAST CARE, 2016, 11 (03) : 167 - 173
  • [37] Advantageous polypharmacology of abemaciclib revealed by omics profiling of CDK4/6 inhibitors
    Hafner, Marc
    Mills, Caitlin E.
    Subramanian, Kartik
    Chen, Chen
    Boswell, Sarah A.
    Everley, Robert A.
    Juric, Dejan
    Sorger, Peter K.
    CANCER RESEARCH, 2018, 78 (04)
  • [38] Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
    La Monica, Silvia
    Fumarola, Claudia
    Cretella, Daniele
    Bonelli, Mara
    Minari, Roberta
    Cavazzoni, Andrea
    Digiacomo, Graziana
    Galetti, Maricla
    Volta, Francesco
    Mancini, Maicol
    Petronini, Pier Giorgio
    Tiseo, Marcello
    Alfieri, Roberta
    CANCERS, 2021, 13 (01) : 1 - 15
  • [39] Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center derived B-cell lymphomas
    Tanaka, Yuka
    Momose, Shuji
    Tabayashi, Takayuki
    Tokihira, Michihide
    Tamaru, Jun-ichi
    Kizaki, Masahiro
    CANCER SCIENCE, 2021, 112 : 547 - 547
  • [40] CDK4/6 inhibitor-associated vortex keratopathy: a case report
    Lian Shu
    Xinhan Cui
    Yan Wang
    Xinghuai Sun
    BMC Ophthalmology, 25 (1)
12345